Memantina Gp (Memantine Hydrochloride)

Memantine Hydrochloride is indicated for disorders of the central nervous system that involve glutamatergic excitotoxicity, primarily Alzheimer’s disease.

• Alzheimer’s disease (mild to moderate): helps maintain cognitive function and daily living activities.
• Alzheimer’s disease (moderate to severe): may slow functional decline and improve global clinical status.
• Alzheimer’s disease with behavioral disturbances: can reduce agitation and improve overall patient behavior.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel at a site distinct from the glutamate binding site, it reduces excessive calcium influx caused by prolonged glutamate activation, thereby limiting excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Headache: transient cranial pain.
• Constipation: reduced bowel motility.
• Confusion: occasional disorientation.
• Fatigue: general tiredness.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring medical attention.
• Cardiac arrhythmia: irregular heart rhythm.
• Severe hepatic injury: signs of liver dysfunction.
• Stevens‑Johnson syndrome: serious skin reaction.
• Suicidal ideation: thoughts of self‑harm.
• Severe rash or hypersensitivity: extensive skin eruption.

Memantine Hydrochloride should be used with caution in specific clinical situations.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic impairment: consider dose reduction.
• History of seizures: monitor for increased seizure activity.
• Cardiovascular disease: observe blood pressure and heart rhythm.
• Concomitant NMDA agonists: avoid combined use due to antagonistic effects.
• Store below 25°C: keep in the original pack, protect from moisture.

Memantine Hydrochloride can interact with several medication classes.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neuropsychiatric effects.
• Other NMDA antagonists (e.g., ketamine): additive central nervous system depression.

Moderate Interactions (Monitor Closely)

• Anticholinesterase inhibitors (e.g., donepezil): may alter efficacy of each agent.
• Antihypertensive drugs: potential additive blood pressure lowering.
• Diuretics: monitor electrolyte balance.
• SSRIs or SNRIs: watch for increased risk of confusion or dizziness.